Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree

In order to help prioritize the selection of candidate genes and to study possible trait and not state related changes in gene expression, we compared lymphocytic gene expression patterns of five individual family members with schizophrenia and nine unaffected individuals from a large multiplex high density pedigree. We screened gene expression by microarray consisting of 1128 brain focused genes. Three criteria for selection of microarray gene differences between schizophrenia and unaffected family members were employed: a significant t-test, expression in a majority of subjects, and fold change magnitude. Gene expression levels were significantly different for nine genes between individuals with schizophrenia compared to unaffected controls, and two genes were validated by real-time PCR. The expression of the neuropeptide Y receptor Y1 gene (NPY1R localized at 4q31.3-q32) and the human guanine nucleotide-binding regulatory protein Go-alpha (GNAO1 localized at 16q13) was significantly decreased in individuals with schizophrenia compared to unaffected family controls by microarray and real-time PCR. The cytosolic malate dehydrogenase gene (MDH1 localized at 2p13.3) was also significantly increased by microarray analysis and showed a trend for increase by real-time PCR. The significant genes are discussed in terms of proximity to linkage regions, prior association studies of schizophrenia, and other reports of microarray screening of schizophrenia tissue. Evidence from these studies taken together with the present study suggests critical pathways in schizophrenia may be studied in peripheral tissue as part of the strategy in functional genomic convergence. This preliminary study needs to be repeated by screening a larger set of genes in additional families with schizophrenia. The present study offers support for examination of gene expression patterns using lymphocytic RNA for complex neuropsychiatric disorders from large cohorts of patients.

[1]  R. Quirion,et al.  Neuropeptide Y (NPY) and depression: from animal studies to the human condition. , 2002, Life sciences.

[2]  M. Owen,et al.  Genome scans and microarrays: converging on genes for schizophrenia? , 2002, Genome Biology.

[3]  Daniel R Weinberger,et al.  Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study , 2002, Schizophrenia Research.

[4]  A D Long,et al.  Improved Statistical Inference from DNA Microarray Data Using Analysis of Variance and A Bayesian Statistical Framework , 2001, The Journal of Biological Chemistry.

[5]  J. Trojanowski,et al.  Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. , 2002, Archives of general psychiatry.

[6]  Peter B. Jones,et al.  Minor physical anomalies in schizophrenia: is age a confounding factor? , 2003, Schizophrenia Research.

[7]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[8]  N. Kuroki,et al.  Morphological changes in neuropeptide Y-positive fiber in the hippocampal formation of schizophrenics , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[9]  W. Maier,et al.  Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis , 1997, Molecular Psychiatry.

[10]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[11]  Peter B. Jones,et al.  Gene expression analysis in schizophrenia: Reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Fuchs,et al.  A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Coon,et al.  Evidence for a chromosome 2p13–14 schizophrenia susceptibility locus in families from Palau, Micronesia , 1998, Molecular Psychiatry.

[15]  J. Kelsoe,et al.  Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. , 2000, Physiological genomics.

[16]  J. Gelernter,et al.  Neuropeptide Y like immunoreactivity in schizophrenia: Relationships with clinical measures , 1991, Schizophrenia Research.

[17]  D. Housman,et al.  Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes , 2000, Molecular Psychiatry.

[18]  L. DeLisi,et al.  Genome-wide scan for linkage to schizophrenia in a Spanish-origin cohort from Costa Rica. , 2002, American journal of medical genetics.

[19]  Y. Kwak,et al.  Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients , 1999, BMC Medical Genetics.

[20]  B. Kolachana,et al.  Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse , 2003, The Pharmacogenomics Journal.

[21]  Y. Hurd,et al.  Neuropeptide Y Y1 and Y2 Receptor mRNA Expression in the Prefrontal Cortex of Psychiatric Subjects , 2001, Neuropsychopharmacology.

[22]  Y. Hurd,et al.  Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[23]  H. Ball,et al.  Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation. , 1997, Genomics.

[24]  D. Collier,et al.  Association study of the CACN1A4 (SCA6) triplet repeat and schizophrenia. , 1999, Psychiatric genetics.

[25]  M. Gladis,et al.  Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. , 2000, American journal of medical genetics.

[26]  D. M. Eadie,et al.  Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. , 1996, Genomics.

[27]  J. Suvisaari,et al.  A genomewide screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple susceptibility loci. , 1999, American journal of human genetics.

[28]  J. Pierri,et al.  Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.

[29]  M. Vawter,et al.  Microarrays: applications in neuroscience to disease, development, and repair. , 2001, Restorative neurology and neuroscience.

[30]  W. Wood,et al.  Assembly and use of a broadly applicable neural cDNA microarray. , 2001, Restorative neurology and neuroscience.

[31]  K. Becker,et al.  AF5, a CNS Cell Line Immortalized with an N-Terminal Fragment of SV40 Large T: Growth, Differentiation, Genetic Stability, and Gene Expression , 2002, Experimental Neurology.

[32]  Pierre Baldi,et al.  A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..

[33]  N. Kiriike,et al.  Association of a GTP-binding protein Goα subunit mutation with schizophrenia , 2001, Molecular Psychiatry.

[34]  J D Terwilliger,et al.  Genome-wide scan in a nationwide study sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 2q and 5q. , 2001, Human molecular genetics.

[35]  S. Hirsch,et al.  Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex , 1996, Biological Psychiatry.

[36]  P. Sternweis,et al.  Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. , 1984, The Journal of biological chemistry.

[37]  M. Owen,et al.  A genomewide linkage study of age at onset in schizophrenia. , 2001, American journal of medical genetics.

[38]  M. Baron,et al.  Genetics of schizophrenia and the new millennium: progress and pitfalls. , 2001, American journal of human genetics.

[39]  R. Ekman,et al.  Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics , 1991, Acta psychiatrica Scandinavica.

[40]  N. Kiriike,et al.  Association of a GTP-binding protein Go alpha subunit mutation with schizophrenia. , 2001, Molecular psychiatry.

[41]  T. Nagasu,et al.  Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. , 2001, Brain research. Gene expression patterns.

[42]  J. Rapoport,et al.  Childhood-onset schizophrenia/autistic disorder and t(1;7) reciprocal translocation: identification of a BAC contig spanning the translocation breakpoint at 7q21. , 2000, American journal of medical genetics.

[43]  R. Straub,et al.  Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes , 2002, Molecular Psychiatry.